Table S1.

Experimental approach and treated groups

Group	Treatment period [final day]	Immunization	Treatment	Mice treated, n
i) TnI-induced EAM till day 270
wt/TnI	0–21 [21]	TnI	—	10
wt/CFA		Control buffer	—	10
wt/TnI	0–90 [90]	TnI	—	8
wt/CFA		Control buffer	—	9
wt/TnI	0–270 [270]	TnI	—	14
wt/CFA		Control buffer	—	15
ii) HMGB1 inhibition in TnI-immunized wt mice
CFA/GL	0–21 [21]	Control buffer	GL	5
TnI/–	0–21 [21]	TnI	1× PBS	5
TnI/GL21	0–21 [21]	TnI	1× PBS	5
TnI/GL14	14–21 [21]	TnI	GL	9
Ab-HMGB1	0–21 [21]	TnI	Ab-HMGB1	9
Ab-Cont.	0–21 [21]	TnI	Ab-Cont.	8
iii) TnI-induced EAM of RAGE knockout (RAGE-ko) mice
wt/TnI	0–21 [21]	TnI	—	20
wt/CFA		Control buffer	—	15
RAGE-ko/TnI		TnI	—	9
RAGE-ko/CFA		Control buffer	—	11
iv) Adeno-associated viral mediated HMGB1 overexpression
wt/Cont./CFA	–14–21 [35]	Control buffer	AAV-luciferase	10
wt/HMGB1/CFA		Control buffer	AAV-HMGB1	15
RAGE-ko/Cont./CFA		Control buffer	AAV-luciferase	9
RAGE-ko/HMGB1/CFA		Control buffer	AAV-HMGB1	8
wt/Cont./TnI		TnI	AAV-luciferase	10
wt/HMGB1/TnI		TnI	AAV-HMGB1	23
RAGE-ko/Cont./TnI		TnI	AAV-luciferase	14
RAGE-ko/HMGB1/TnI		TnI	AAV-HMGB1	9

Dashes indicate that there was no other treatment except for the immunization with TnI or CFA.